OakChart

Valneva SE ADR

VALNHealthcare·Biotechnology·France·Small·NASD·Nov 11 • 7:14 AM ET

5.80-0.07 (-1.19%)
2026-11-11 14:46 CET
Market cap
558.40 USD m
Revenue, TTM
166.65 USD m
Net income, TTM
-183.86 USD m
Free cash flow, TTM
-100.74 USD m
EPS diluted, TTM
-2.09
P/E
-
Compare

Price

VALN against its 20, 50 and 200-day averages
2050200missearnings
5.006.007.008.009.001.4M2.9MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VALNclose 5.8020-day 5.5950-day 6.02200-day 6.655.80

52.4% under 12.18 on 24 Feb 2026. Last 15 sessions, 15.0% high to low

Profile

VALN
52-week range, 14% of the way up
4.7512.18

Valneva SE is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. It currently provides three proprietary travel vaccines: IXIARO, DUKORAL, and IXCHIQ. The IXIARO is an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis in adults, adolescents, children, and infants aged two months and older. The DUKORAL is a drinkable vaccine that helps prevent diarrhea caused by heat-labile toxin-producing ETEC, as well as cholera. The IXCHIQ is a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also offers additional vaccines, including VLA1553, VLA15, VLA160, VLA200, VLA1601 and others. Valneva was founded on May 28, 2013 and is headquartered in Saint-Herblain, France.

Employees674
IPOMay 06, 2021
Beta1.42
ATR, 14d0.23
Rel volume0.12
Short float0.05%
Insider own3.22%
Inst own0.76%

Snapshot

6 groups

Valuation

Index-
Market Cap551.75M
Enterprise Value653.17M
Income-183.86M
Sales166.65M
Book/sh0.98
Cash/sh1.46
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees674
IPOMay 06, 2021

Ratios

P/E-
Forward P/E9.10
PEG-
P/S3.31
P/B5.93
P/C3.97
P/FCF-
EV/EBITDA-
EV/Sales3.92
Quick Ratio1.69
Current Ratio2.16
Debt/Eq2.59
LT Debt/Eq2.33
Option/ShortNo / Yes

Earnings

EPS (ttm)-2.09
EPS next Y0.64
EPS next Q-0.20
EPS this Y34.96%
EPS next Y161.52%
EPS next 5Y-
EPS past 3/5Y16.00% 0.90%
Sales past 3/5Y-19.63% 9.40%
EPS Y/Y TTM-134.63%
Sales Y/Y TTM-21.91%
EPS Q/Q-136.61%
Sales Q/Q-25.85%
EarningsNov 24 BMO
EPS/Sales Surpr.-82.17% -18.31%

Ownership

Insider Own3.22%
Insider Trans0.00%
Inst Own0.76%
Inst Trans11.93%
ROA-36.82%
ROE-118.01%
ROIC-59.52%
Gross Margin16.40%
Oper. Margin-86.72%
Profit Margin-110.32%
SMA203.83%
SMA50-3.69%
SMA200-12.81%
Trades-

Technical

Shs Outstand94.82M
Shs Float92.06M
Short Float0.05%
Short Ratio0.65
Short Interest0.05M
52W High12.18 -52.38%
52W Low4.75 22.11%
Volatility3.45% 3.37%
ATR (14)0.23
RSI (14)52.42
Beta1.42
Rel Volume0.12
Avg Volume74.12K
Volume457

Performance

Perf Week3.02%
Perf Month4.32%
Perf Quarter2.65%
Perf Half Y-1.19%
Perf YTD-34.24%
Perf Year-34.76%
Perf 3Y-58.03%
Perf 5Y-88.38%
Perf 10Y-
Recom1.44
Target Price12.26
Prev Close5.87
Price5.80
Change %-1.19%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Aug 11, 2026InitiatedTTD CowenBuy$12+106.9%
Apr 22, 2026DowngradeGGoldmanNeutral → Sell$4.90-15.5%
Aug 19, 2025ResumedHH.C. WainwrightBuy$18+210.3%
Aug 03, 2022InitiatedHH.C. WainwrightBuy$34+486.2%

Peers

Mkt cap
TickerCompanyMkt cap
NVAXNovavax Inc1.70B
EBSEmergent Biosolutions Inc308.49M
ARCTArcturus Therapeutics Holdings Inc268.05M
MRNAModerna Inc102.91B
PCVXVaxcyte Inc10.50B
PFEPfizer Inc165.75B
INOInovio Pharmaceuticals Inc144.76M
BNTXBioNTech SE ADR21.70B
GOVXGeovax Labs Inc1.36M
GSKGSK Plc ADR101.05B

News

latest 14 of 206
  • MHRA revokes approval for Valnevas Ixchiq due to safety frailties (Pharmaceutical Technology)
  • Valneva Shares Fall as UK Withdraws Approval for Ixchiq Chikungunya Vaccine (InvestorsHub)
  • VALN Stock Plunges 7% After-Hours As UK Revokes Valnevas IXCHIQ Authorization In Latest Market Setback (Stocktwits)
  • Valneva ADRs fall as UK revokes IXCHIQ marketing authorization (Investing.com)
  • Why Did VALN Stock Surge 24% Today? (Stocktwits) +26.19%
  • Loading…
  • Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers (BioPharma Dive)
  • Pfizer and Valnevas Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency (Business Wire)
  • Valneva SE (INRLF) (H1 2026) Earnings Call Highlights: Strategic Pivot and Lyme Vaccine ... (GuruFocus.com)
  • Valneva SE (INRLF) Q1 2026 Earnings Call Highlights: Promising Vaccine Developments Amid ... (GuruFocus.com)
  • Will Pfizers Lyme disease gamble pay off or set the space back? (Pharma Voice)
  • Pfizer-Valneva Lyme disease vaccine falls short as low cases skew results (Clinical Trials Arena) -37.11%
  • Mixed results for Lyme disease vaccine hit Valneva shares (AFP)
  • Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results (BioPharma Dive)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-24--0.196--43.675
2026Q22026-08-13-0.376-0.206-0.38339.3848.215
2026Q12026-05-13-0.417-0.149-0.43636.1854.693
2025Q42026-03-17-0.688-0.359-0.67155.4852.464
2025Q32025-11-20-0.502-0.326-0.60431.9148.854
2025Q22025-08-12-0.150-0.324-0.16255.9453.163
2025Q12025-05-07-0.140-0.278-0.12055.9344.553
2024Q42025-03-20-0.406-0.187-0.48659.6957.343
2024Q32024-12-10-0.111--0.12547.68--
2024Q22024-08-13-0.343-0.341-0.38741.4244.734
2024Q12024-05-060.8841.1200.92135.3071.994
2023Q42024-03-20-0.5390.094-0.49847.0176.823
2023Q32023-11-09-0.482-0.448-0.53740.0445.073
2023Q22023-09-20-0.191-0.276-0.26542.7434.462
2023Q12023-05-04-0.286-0.388-0.28136.8633.114
2022Q42023-03-23-0.5030.241-0.652121.35158.274

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.036-0.072-0.043136.4139.51
2020FY-1.686-1.666-1.618130.97144.15
2021FY-1.489-0.427-1.778383.17293.45
2022FY-2.344-1.110-2.608391.47370.09
2023FY-1.607-1.288-1.582166.83203.17
2024FY-0.223-0.067-0.182191.52192.65
2025FY-1.610-1.155-1.586201.12197.14
2026FY--1.036--173.4
2027FY-0.637--331.94
2028FY-0.340--280.74
2029FY-0.687--348.21
2030FY-1.677--480.01

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2750143.6739.8352.00
2026Q3S2026-10-2652343.6739.8352.00
2026Q3S2026-10-0552243.7839.8352.00
2026Q3S2026-08-1352243.7939.8352.02
2026Q3S2026-08-1050141.7238.4445.63
2026Q3S2026-07-2740140.7438.4442.98
2026Q3S2026-07-2042240.7438.4442.98
2026Q3S2026-05-1443140.9939.4642.98
2026Q3S2026-05-1343141.0239.4643.09
2026Q3S2026-04-2141236.4226.3048.24
2026Q3S2026-03-1840236.2426.3048.24
2026Q3S2026-03-1730138.3726.3048.46
2026Q3S2026-03-1130138.3426.2348.46
2026Q3S2026-02-1930038.6226.2349.28

Estimate history

EPS, annual-0.3380.094-0.043-1.618-1.778-2.608-1.582-0.182-1.546-2.0938
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.387-0.125-0.486-0.12-0.162-0.604-0.671-0.436-0.383
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual118.761133.353141.245125.763411.431379.72166.182183.432197.116166.65
Period201720182019202020212022202320242025TTM
Sales, quarterly40.97550.3456.47351.81554.7834.36855.50636.15540.622
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual38.69845.3645.36645.40252.53369.11169.39481.19986.70894.823
Period201720182019202020212022202320242025MRQ
Shares, quarterly69.39481.07681.19981.19985.03285.86586.70886.04594.823
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue166.65197.12183.43166.18379.72411.43125.76141.24133.35
Cost of Goods Sold Incl. D&A139.31126.33114.59113.71346.13224.6067.3360.9256.19
Gross Profit27.3470.7868.8452.4833.59186.8358.4380.3277.17
Selling, General and Administrative Excl. Other171.86175.13175.07164.49165.64282.65142.9088.3274.50
Research and Development96.9291.8773.3961.51106.49199.2691.6041.1729.84
Other Operating Expense-0.420.370.510.230.250.190.160.16
Operating Income-144.52-104.77-106.60-112.52-132.27-96.07-84.66-8.172.51
Interest Expense47.3147.2925.9425.2220.0320.0512.242.954.47
Unusual Expense0.00-6.72-11.80-12.32-0.17-3.05-2.112.850.03
Net Income Before Taxes-183.75-134.37-23.27-113.98-168.34-108.65-85.62-9.802.63
Income Taxes0.10-4.37-10.02-4.32-17.74-21.87-12.36-6.090.10
Consolidated Net Income-183.86-130.00-13.25-109.66-150.58-86.79-73.41-1.953.85
Net Income From Continuing Operations-183.86-130.00-13.25-109.66-150.58-86.79-73.41-1.953.85
Net Income-183.86-130.00-13.25-109.66-150.58-86.79-73.41-1.953.85
EPS (Recurring)-1.94-1.60-0.30-1.71-2.61-1.82-1.650.000.09
EPS (Basic, Before Extraordinaries)-2.09-1.55-0.18-1.58-2.61-1.78-1.62-0.040.10
EPS (Diluted)-2.09-1.55-0.18-1.58-2.61-1.78-1.62-0.040.09
EBITDA-120.03-79.21-85.42-93.51-110.17-79.19-73.491.3810.56
Non-Operating Income (Expense)8.0810.9697.4811.44-16.204.419.184.164.63
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-8.107.074.99-4.1112.752.071.971.49
Price To Sales Ratio2.983.761.744.321.936.59---
Gross Margin16.4035.9137.5331.588.8545.4146.4656.8757.87
Operating Margin-86.72-53.15-58.12-67.71-34.83-23.35-67.32-5.781.88
Net Margin-110.32-65.95-7.22-65.99-39.66-21.09-58.37-1.382.89
Shares Outstanding94.8286.7181.2069.3969.1152.5345.4045.3745.36
Market Capitalization558.40558.40355.00719.47879.012,912.882,876.14--

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue40.6236.1655.5134.3754.7851.8156.4750.34
Cost of Goods Sold Incl. D&A38.7630.6341.9827.9427.3424.2529.0528.21
Gross Profit1.865.5313.526.4327.4427.5627.4222.13
Selling, General and Administrative Excl. Other33.4835.5149.0253.8542.4836.1155.9145.18
Research and Development17.4617.8029.7731.8919.8215.7427.2820.74
Other Operating Expense0.000.000.00-0.000.000.00-
Operating Income-31.62-29.98-35.49-47.42-15.03-8.55-28.48-23.05
Interest Expense6.045.9628.686.636.356.296.696.30
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-36.94-36.56-59.45-50.80-13.38-8.17-34.51-14.23
Income Taxes-0.660.96-1.231.03-0.251.554.95-4.09
Consolidated Net Income-36.28-37.52-58.22-51.83-13.13-9.72-39.45-10.15
Net Income From Continuing Operations-36.28-37.52-58.22-51.83-13.13-9.72-39.45-10.15
Net Income-36.28-37.52-58.22-51.83-13.13-9.72-39.45-10.15
EPS (Recurring)-0.38-0.44-0.67-0.60-0.16-0.12-0.49-0.13
EPS (Basic, Before Extraordinaries)-0.38-0.44-0.67-0.60-0.16-0.12-0.49-0.13
EPS (Diluted)-0.38-0.44-0.67-0.60-0.16-0.12-0.49-0.13
EBITDA-26.20-23.67-29.03-41.13-8.90-2.86--
Non-Operating Income (Expense)0.72-0.624.723.258.006.670.6715.11
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Price To Sales Ratio2.982.973.895.312.162.731.942.85
Gross Margin4.5815.2924.3618.7150.1053.2048.5643.96
Operating Margin-77.83-82.93-63.95-137.99-27.44-16.50-50.43-45.79
Net Margin-89.31-103.78-104.89-150.82-23.97-18.75-69.86-20.16
Shares Outstanding94.8286.0486.7185.8785.0381.2081.2081.08
Market Capitalization558.40537.78758.911,047.56482.13544.84355.00489.70

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments128.78174.24139.27308.90394.25250.1472.3393.4245.70
Short Term Receivables32.6636.4546.0025.5250.0523.5326.9712.8721.16
Inventories58.9955.5749.1237.46141.1232.9528.9325.9823.93
Other Current Assets40.9243.3655.9381.3480.7870.7516.7511.739.41
Total Current Assets261.36309.63290.33453.22666.21377.38144.98144.00100.20
Net Property, Plant & Equipment162.11163.73172.98164.40197.6895.6277.8343.4446.08
Total Investments and Advances0.000.000.000.002.422.612.541.480.00
Intangible Assets26.2526.1528.2430.6437.1943.3246.9451.3258.20
Deferred Tax Assets9.7820.0417.5918.0313.9519.8616.1714.422.02
Other Assets8.918.339.388.8621.9323.8319.2619.5020.85
Total Assets468.41527.88518.51675.14939.37562.62307.73274.16227.36
Short Term Debt Incl. Current Port. of LT Debt24.2524.1951.8739.4811.6511.854.8320.0420.89
Accounts Payable10.6613.0919.4015.4818.2430.469.9510.496.31
Income Tax Payable0.001.800.700.570.090.002.761.610.39
Other Current Liabilities74.7179.57103.52240.52389.63172.8728.8116.9617.65
Total Current Liabilities109.62118.65175.49296.05419.60215.1946.3649.0945.24
Long Term Debt219.16199.80178.80123.15118.74117.1890.8245.8164.96
Provision for Risks Charges1.630.571.191.419.452.890.480.000.35
Deferred Tax Liabilities5.1814.4114.3212.7511.3413.5510.5711.340.08
Other Liabilities8.146.777.057.21186.25119.097.784.245.46
Total Liabilities343.72340.19376.84440.56745.38467.89156.02110.48116.09
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity124.69187.69141.67234.58193.9994.73151.71163.68111.28
Total Shareholders Equity124.69187.69141.67234.58193.9994.73151.71163.68111.28
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity124.69187.69141.67234.58193.9994.73151.71163.68111.28
Total Liabilities & Stockholders Equity468.41527.88518.51675.14939.37562.62307.73274.16227.36
Book Value Per Share1.442.312.043.393.692.093.303.562.83
Tangible Book Value Per Share1.141.991.632.952.981.132.312.481.37
Full-Time Employees674713676----480457
Price to Book Ratio6.001.464.324.6115.0429.92---
Return on Assets-26.10-2.53-18.37-18.65-11.56-16.87-0.671.54-5.81
Return on Equity-83.23-8.04-58.29-70.27-60.12-59.57-1.242.80-11.95
Return on Invested Capital-37.81-3.42-34.22-42.09-27.75-34.64-0.801.84-7.35
Quick Ratio1.852.141.371.401.251.602.502.401.69
Current Ratio2.382.611.651.531.591.753.132.932.22

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-181.87-130.00-13.25-109.66-150.58-86.79-73.41-1.953.85
Depreciation-24.5521.1919.0122.1116.8811.179.588.06
Other Funds (Non Cash)26.2514.08-85.2614.73-138.01104.2025.523.33-2.04
Funds from Operations-130.58-90.63-79.43-74.08-269.0838.31-37.7110.969.87
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital32.64-1.66-12.32-157.391.8242.70189.48-7.484.67
Cash from Operating Activities-97.94-92.29-91.75-231.47-267.2681.01151.773.4814.53
Capital Expenditures-2.81-5.06-17.79-15.47-30.82-110.13-22.20-12.18-3.74
Net Assets From Acquisitions0.000.000.00-11.840.000.000.000.00-
Sale of Fixed Assets and Businesses0.320.140.180.120.010.000.000.000.09
Purchase or Sale of Investments1.970.950.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments1.970.950.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.0098.253.630.000.000.030.000.00
Cash from Investing Activities-5.20-3.9680.64-23.56-30.81-110.13-22.17-12.18-3.65
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock53.3933.8661.81-0.26199.51197.180.33-2.7658.12
Repurchase of Common Pref Stock0.000.000.00-0.260.000.000.00-2.78-0.03
Sale of Common Pref Stock53.3933.8661.810.00199.51197.180.330.0258.15
Proceedsfrom Stock Options53.3933.8661.810.00199.51197.180.330.0258.15
Issuance or Reduction of Debt, Net-3.13-4.0885.4239.45-1.3032.230.11-16.70
Change in Long Term Debt--------0.00
Issuance of Long Term Debt--------0.00
Reduction of Long Term Debt--------0.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities63.0433.9354.7981.78235.76192.5730.15-5.6841.42
Exchange Rate Effect0.73-3.831.96-0.22-0.874.68-0.210.23-0.94
Net Change in Cash-44.96-66.1645.64-173.47-63.17168.13159.55-14.1551.37
Free Cash Flow-100.74-97.28-106.75-246.85-297.99-28.00130.18-8.2811.14
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.75-2.111.83-2.594.01-0.990.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments138.94121.29128.78168.57189.35165.26
Short Term Receivables18.6811.6732.6623.5928.3236.21
Inventories55.0658.2858.9975.5472.4666.63
Other Current Assets42.1340.8540.9247.5944.0941.97
Total Current Assets254.82232.10261.36315.29334.22310.07
Net Property, Plant & Equipment146.89153.94162.11166.93173.08166.69
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets23.9124.9226.2527.1127.9726.57
Deferred Tax Assets9.678.949.788.629.408.58
Other Assets8.638.738.918.7210.139.02
Total Assets443.92428.63468.41526.67554.79520.92
Short Term Debt Incl. Current Port. of LT Debt24.1924.2124.2572.2757.1324.20
Accounts Payable12.4825.1228.8235.396.6730.07
Income Tax Payable0.170.070.000.341.881.68
Other Current Liabilities81.3059.1556.5568.8281.8358.77
Total Current Liabilities118.14108.56109.62176.82147.51114.72
Long Term Debt216.17217.18219.16157.84174.03203.88
Provision for Risks Charges1.291.381.632.731.510.71
Deferred Tax Liabilities5.105.105.184.644.744.46
Other Liabilities10.478.038.147.838.177.84
Total Liabilities351.17340.26343.72349.86335.95331.61
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity92.7588.37124.69176.81218.84189.31
Total Shareholders Equity92.7588.37124.69176.81218.84189.31
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity92.7588.37124.69176.81218.84189.31
Total Liabilities & Stockholders Equity443.92428.63468.41526.67554.79520.92
Book Value Per Share0.981.031.442.062.572.33
Tangible Book Value Per Share0.730.741.141.742.242.00
Full-Time Employees634-674-700-
Price to Book Ratio6.004.354.284.532.432.90
Return on Assets-36.82-33.85-26.68-20.69-13.74-16.20
Return on Equity-118.01-115.75-85.09-54.41-36.49-43.77
Return on Invested Capital-11.74-12.28-16.93-15.49-3.34-2.47
Quick Ratio1.691.601.851.361.772.12
Current Ratio2.162.142.381.782.272.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-36.46-37.52-57.06-50.82-12.90-9.72
Other Funds (Non Cash)-1.7312.19-11.8327.63-7.425.75
Funds from Operations-26.80-25.34-43.50-34.94-8.57-3.96
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital5.6920.15-3.4410.240.77-9.23
Cash from Operating Activities-21.11-5.19-46.94-24.70-7.81-13.19
Capital Expenditures-0.40-0.29-1.25-0.86-1.41-1.55
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.190.000.060.070.020.00
Purchase or Sale of Investments0.510.510.950.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.510.510.950.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.300.22-5.56-0.163.29-1.55
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock40.201.084.417.7021.870.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock40.201.084.417.7021.870.00
Proceedsfrom Stock Options40.201.084.417.7021.870.00
Issuance or Reduction of Debt, Net0.00-0.604.74-1.600.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities39.64-0.5624.26-0.3010.83-0.72
Exchange Rate Effect0.180.400.34-0.20-3.37-0.62
Net Change in Cash19.02-5.13-38.46-20.398.52-16.08
Free Cash Flow-21.51-5.48-48.19-25.56-9.23-14.67

Revenue breakdown

Total Biological Products, (No Diagnostic Substances) revenue2024: 183.48M 2025: 197.00M
Austria2024: 17.20M 2025: 10.68M
Canada2024: 34.97M 2025: 33.98M
France2024: 7.81M 2025: 16.54M
Germany2024: 19.88M 2025: 19.70M
Nordics2024: 15.08M 2025: 15.68M
Other Europe2024: 9.80M 2025: 15.65M
Other countries2024: 5.08M 2025: 10.04M
United Kingdom2024: 21.09M 2025: 14.26M
United States2024: 52.58M 2025: 60.47M
Total Biological Products, (No Diagnostic Substances) revenue2024: 183.48M 2025: 197.00M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-300.05%0.0M92.1M76.11K
2026-10-150.21%0.2M91.8M75.57K
2026-09-300.23%0.2M91.8M76.78K
2026-09-150.21%0.2M91.8M77.69K
2026-08-310.21%0.2M91.8M74.63K
2026-08-140.17%0.2M91.8M74.75K
2026-07-310.18%0.2M90.3M29.89K
2026-07-150.18%0.2M90.3M49.15K
2026-06-300.20%0.2M90.3M63.75K
2026-06-150.19%0.2M90.3M92.51K
2026-05-290.20%0.2M89.9M91.78K
2026-05-150.18%0.2M89.9M89.36K
2026-04-300.17%0.2M89.8M85.81K
2026-04-150.18%0.1M81.5M65.40K
2026-03-310.19%0.2M81.5M54.06K
2026-03-130.21%0.2M81.5M18.75K
2026-02-270.17%0.1M81.5M19.48K
2026-02-130.17%0.1M81.5M18.76K
2026-01-300.18%0.1M81.4M20.09K
2026-01-150.18%0.1M81.4M23.27K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-10-156-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-10-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-08-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-30SEC
2026-07-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-06-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-06-16EFFECTEffectiveness filing by commission orderSEC
2026-06-16424B3SEC
2026-06-12CORRESPSEC
2026-06-11UPLOADUpload SubmissionSEC
2026-06-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-06-04F-3Registration statement for specified transactions by certain foreign private issuersSEC
2026-06-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-05-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-31SEC
2026-05-12SCHEDULE 13GSEC
2026-05-12SCHEDULE 13D/ASEC
2026-05-056-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-04-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-03-266-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-03-236-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-03-186-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-03-1720-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-10SCHEDULE 13D/ASEC
2026-03-096-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-03-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-02-196-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-02-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-02-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC
2026-01-206-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Frazier Life Sciences Management, L.P.2.42%
Vivo Capital, LLC0.80%
GENERAL AMERICAN INVESTORS CO INC0.37%
MILLENNIUM MANAGEMENT LLC0.14%
WELLS FARGO & COMPANY/MN0.08%
MORGAN STANLEY0.06%
IRONWOOD INVESTMENT MANAGEMENT LLC0.05%
CITADEL ADVISORS LLC0.02%
XTX Topco Ltd0.02%
VSM Wealth Advisory, LLC0.01%

Funds

Fund% owned
GENERAL AMERICAN INVESTORS CO INC0.37%
Fidelity Nasdaq Composite Index Fund0.01%

OakChart. VALN. Cached 15 minutes.

Some panels did not load: insider.